论文部分内容阅读
目的讨论联合检测血清CA125和CA72-4的含量对卵巢癌早期诊断的临床价值。方法用电化学发光免疫测定法测定卵巢癌患者94例,卵巢良性肿瘤患者136例,及健康妇女80例的血清样品中CA125和CA72-4含量。结果与卵巢良性肿瘤组和健康妇女组相比,卵巢癌患者血清CA125和CA72-4的含量和阳性率明显升高(P<0.01),两项标志物的阳性率分别是87.23%和68.08%,联合检测阳性率为91.5%。结论两项肿瘤标志物对卵巢肿瘤的良恶性辅助诊断及鉴别诊断具有一定应用价值,联合检测可以提高早期卵巢癌的阳性诊断率。
Objective To discuss the clinical value of combined detection of serum CA125 and CA72-4 in the early diagnosis of ovarian cancer. Methods The levels of CA125 and CA72-4 in serum samples of 94 patients with ovarian cancer, 136 patients with benign ovarian tumor and 80 healthy women were determined by electrochemiluminescence immunoassay. Results Compared with benign ovarian tumor group and healthy women group, the levels and positive rates of serum CA125 and CA72-4 in patients with ovarian cancer were significantly increased (P <0.01). The positive rates of the two markers were 87.23% and 68.08% , The positive rate of joint detection was 91.5%. Conclusion The two tumor markers have a certain value in the diagnosis and differential diagnosis of benign and malignant ovarian tumors. Combined detection can improve the positive diagnosis rate of early ovarian cancer.